Evidence map›Paper›PMID 39350417›Full record

ArticlePharmaceutical nanotechnology2026

The Second Hyper-Zagreb Index and Coindex of Chemical Nano-structures in Drugs.

Mohammed Alsharafi, Yusuf Zeren, Haifa Ahmed, Abdu Alameri

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical nanotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mohammed AlsharafiDepartment of Mathematics, Faculty of Arts and Science, Yildiz Technical University, Esenler, Istanbul, 34220, Turkey.ORCID 0000-0001-6252-8968
Yusuf ZerenDepartment of Mathematics, Faculty of Arts and Science, Yildiz Technical University, Esenler, Istanbul, 34220, Turkey.ORCID 0000-0001-8346-2208
Haifa AhmedDepartment of Mathematics, Faculty of Education, Art and Science, Aden University, Aden, Yemen.ORCID 0000-0002-4881-6493
Abdu AlameriDepartment of Biomedical Engineering, Faculty of Engineering, University of Science and Technology, Sana'a, Yemen.ORCID 0000-0002-9920-4892

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionVarious dendrimer nanoparticles have properties like multivalency, controlled size, and surface functionality that make them promising nanocarriers for targeted drug delivery and other applications in pharmaceutical sciences. The precise tunability of dendrimers is an advantage over other nanoparticles. The topological descriptors can be used to predict the physicochemical properties of dendrimers and optimize their branching pattern for specific applications. The second hyper-Zagreb index and co-index are computed for various chemical structures, including dendrimers, to facilitate the correlation between their structure and biological activity.

methodsIn this study, the second Hyper-Zagreb index and second Hyper-Zagreb polynomials were calculated for various chemical structures, such as the molecular graph of poly(propyl) ether imine dendrimer PETIM, nanostar dendrimer (D

resultsBy computing formulae and analyzing data and figures, we obtained new insights into the features of structure-property connections for these types of compounds of nanostar dendrimers.

conclusionThe results can be used to optimize the properties of dendrimers for specific applications.

Indexed as

DendrimersNanoparticlesDrug CarriersPharmaceutical PreparationsDendrimersDrug CarriersPharmaceutical Preparationsdendrimersmolecular graphnanostarsecond Hyper-Zagreb coindexSecond Hyper-Zagreb index

Identifiers

PMID39350417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.